2013
DOI: 10.1016/j.bbr.2013.04.012
|View full text |Cite
|
Sign up to set email alerts
|

Effects of a dopamine D1 agonist on ketamine-induced spatial working memory dysfunction in common marmosets

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
16
0

Year Published

2013
2013
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 35 publications
(16 citation statements)
references
References 34 publications
0
16
0
Order By: Relevance
“…Importantly, however, ketamine has been shown to affect D2-like dopamine receptors, but to have less pronounced effects on D1 receptors (Li et al, 2015). Indeed, D1 agonists have been demonstrated to antagonize the ketamine-induced effects of cognitive impairment in marmosets (Nakako et al, 2013). Hence, potential effects of ketamine anesthesia might have rather led us to underestimate the network effect of D1-based dopamine.…”
Section: Methodological Considerationsmentioning
confidence: 99%
“…Importantly, however, ketamine has been shown to affect D2-like dopamine receptors, but to have less pronounced effects on D1 receptors (Li et al, 2015). Indeed, D1 agonists have been demonstrated to antagonize the ketamine-induced effects of cognitive impairment in marmosets (Nakako et al, 2013). Hence, potential effects of ketamine anesthesia might have rather led us to underestimate the network effect of D1-based dopamine.…”
Section: Methodological Considerationsmentioning
confidence: 99%
“…For those with hand preferences, the preferred hand often depends on their postural position (Hook and Rogers, 2008; Hashimoto et al, 2013). Marmosets have also been taught to perform memory-guided sequences of reaching movements to positions on a touch screen (Nakako et al, 2013) and to perform reaches to eccentric positions while under head and body restraint (Pohlmeyer et al, 2013). …”
Section: Comparing Marmoset and Macaque Visionmentioning
confidence: 99%
“…Studies in monkeys encourage this possibility: The cognitive deficits induced by the NMDA antagonist, ketamine, were ameliorated by D1 agonist treatment (Roberts et al 2010; Nakako et al 2013). D1 agonists are currently being tested in patients with schizophrenia and those with schizotypal symptoms.…”
Section: The Neurobiological Foundations Of Schizophreniamentioning
confidence: 99%